Clinical Data ADC Therapeutics slumps on cancer drug safety scare PharmaphorumShares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control.OncologyRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) Pharmaphorum Shares in ADC Therapeutics fell more than 50% after a non-Hodgkin lymphoma trial showed more deaths with its Zynlonta drug compared to a control. Oncology Read full story Post navigation Previous: Peptide biotech Parabilis targets up to $476M IPONext: SCOTUS backs generic firm Hikma in skinny label dispute Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026